Challenges in Cancer Treatment
Prevalence: Cancer is a leading cause of death globally, with approximately 9.6 million deaths per year.
Side Effects: Common treatments like chemotherapy and radiotherapy can have significant adverse effects, including but not limited to: Hair loss (alopecia); Anemia and; Skin damage (post-radiative dermatitis)
Complexities: Advanced stages of cancer often lead to treatment resistance. The overall health of the patient can deteriorate, leading to treatment failure
Presenting
IMDENDRIM
IMDENDRIM's Edge in Nanomedicine for Cancer Treatment
Unique Value Proposition
of IMDENDRIM
- IMDENDRIM utilizes advanced nanotechnology to target solid tumors with unprecedented precision, minimizing damage to surrounding healthy tissues and reducing side effects typically associated with conventional cancer treatments.
Proprietary Technology
and
Patents
- Awarded with a world patent
(World Patent: PCT/182014/058238) which include the unique mechanisms of action, delivery systems and manufacturing processes that contribute to IMDENDRIM's effectiveness and safety.
Strategic Positioning and
Market
Opportunity
- With the cancer therapies market expected to soar beyond $400 billion by 2033, whilst IMDENDRIM is perfectly placed to meet the increasing demand for cancer treatments that are both effective and less invasive. This market trend presents a prime opportunity for IMDENDRIM to shine.
Nano Gun Technology
Leadership Profile
Founded in 2017 by the Inventors of the Imdendrim Patent
A Young and Innovative Biotech Company
Our Team
Extensive Expertise in Pharmaceutical Research
HAFID BELADJ-TAHAR
NGT’S CO-FOUNDER AND MEDICAL DIRECTOR
Qualifications
PhD in ChemistryMD in PharmacologyDES in Oncology-Radiotherapy
Multidisciplinary Partnership Phases
Chemical/Pharmaceutical Production
(GMP Kit)
- Production of nanomedicine kits (Colcom/ERAS lab/ NGT)
- Natives DGL, Customization, Scale-up, GMP
Radio-pharmaceutical Production
(GMP)
- Labelling and quality control (Radio pharmacy platform
- Radio Labelling, automatic process, TLC control, GMP Production/lot
Pre-clinical Expertise
- Invitro and In vivo tests (CELVAX labs, AFPREMED)
- Molecular biology, Human tumor/tissue samples, Pharmacokinetic & pharmacodynamic models
Market Analysis
The global market for cancer therapies was valued at approximately USD 158 billion in 2020 and is projected to reach about USD 268 billion by 2026, marking a significant growth trend with a Compound Annual Growth Rate (CAGR) of 9.15% over the forecast period. This growth is reflective of the increasing demand for personalized medicine, rising government initiatives for cancer awareness, and the growing prevalence of cancer worldwide.
Among the various segments within the cancer therapy market, the treatment segment, including traditional chemotherapy, targeted therapy, immunotherapy, and hormonal therapy, dominates due to its effectiveness and advancements in reducing side effects compared to traditional methods.
$220 BN
2023 Market Valuation
Estimated to reach $490 BN by 2032
9.15%
CAGR in 2020
IMDENDRIM in Lung Cancer Treatment
Imdendrim has been demonstrated as safe and welltolerated in clinical trials.
All 5 patients showed positive responses at 12 weeks, withtwo achieving complete remission.
The award from CONQUER CANCER® at the BreakthroughSummit recognizes the groundbreaking impact of thisresearch.
Ongoing Clinical Trial:
MDENDRIM's Impact on Lung Cance
- Currently, 12 patients are actively participating in the trial.
- Significant findings have been published in various medical journals,demonstrating the potential of
IMDENDRIM:
- Belhadj-Tahar, Hafid, et al. "In situ anti-cancer agent derived from[^188Re] rhenium nitro-imidazole ligand loaded poly-l-lysinedendrimer administered by direct CT guided stereotactic intrahepaticinjection." Journal of Clinical Oncology, vol. 36, no 15_suppl.
- H. Belhadj-Tahar, N. Sadeg, and G. Yang. "Intra-Tumoral HepaticAdministration Under CT Stereotactic and Ultrasound Guidance of inSitu Anti-Cancer Agent Derived from [^188Re] Rhenium NitroImidazole Ligand Loaded 5th Generation Poly-L-Lysine Dendrimer."International Journal of Radiation Oncology, Biology, Physics 105.1(2019): E642.
Future Directions
Clinical Trials for Aggressive
& Lethal Cancers (Pancreas, Brain, Lung)
Timeframe: 6-12 months
Action Items: List of trial phases (Phase I/II, etc.)
Marketing Authorization
(European Marketing)
Timeframe: 24 months
Action Items: Regulatory submissions,
interactions with EMA, etc.
Business Expansion
(International)
Timeframe: 60 months
Action Items: Strategic partnerships,
global market analysis, etc.
Get in touch
Contact us for futher information or if you want to donate to our research,
reach out
to us at contact@nanoguntechnology.com